Gram-Scale Synthesis of the C14–C23 Fragment of Eribulin
- Qiuhan YuQiuhan YuDepartment of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of ChinaMore by Qiuhan Yu
- ,
- Yueer ZhouYueer ZhouDepartment of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of ChinaMore by Yueer Zhou
- ,
- Xinai GaoXinai GaoDepartment of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of ChinaMore by Xinai Gao
- ,
- Shuheng PanShuheng PanDepartment of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of ChinaMore by Shuheng Pan
- ,
- Feng Lin*Feng Lin*Email: [email protected]WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. of ChinaMore by Feng Lin
- , and
- Wei Li*Wei Li*Email: [email protected]Department of Medicinal Chemistry School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, P. R. of ChinaMore by Wei Li
Abstract
Eribulin is a structurally simplified and completely synthetic analogue of macrocyclic ketone halichondrin B. In 2010, eribulin was approved by FDA for the treatment of metastatic breast cancer (MBC). Although several research groups have reported the synthetic efforts toward eribulin, it is still a challenge to prepare eribulin in a large scale due to its complex molecular architecture. Herein, we report a novel and efficient route to the C14–C23 fragment of eribulin from cheap l-arabinose.
Cited By
This article has not yet been cited by other publications.